Masashi Namba

1.1k total citations
46 papers, 879 citations indexed

About

Masashi Namba is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Masashi Namba has authored 46 papers receiving a total of 879 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 12 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Masashi Namba's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers), Coronary Interventions and Diagnostics (5 papers) and Acute Myocardial Infarction Research (5 papers). Masashi Namba is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers), Coronary Interventions and Diagnostics (5 papers) and Acute Myocardial Infarction Research (5 papers). Masashi Namba collaborates with scholars based in Japan and United States. Masashi Namba's co-authors include Junichi Yoshikawa, Kenei Shimada, Yukio Nishida, Takahiko Kawarabayashi, Toshihiko Sano, Daiju Fukuda, Hiroshi Iwao, Shokei Kim, Yumei Zhan and Atsushi Tanaka and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Masashi Namba

41 papers receiving 851 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Masashi Namba Japan 14 310 287 277 162 113 46 879
L Simonet United States 13 325 1.0× 271 0.9× 342 1.2× 94 0.6× 120 1.1× 22 1.0k
Toshiyuki Kozai Japan 13 368 1.2× 408 1.4× 264 1.0× 104 0.6× 138 1.2× 21 944
Fu-Li Xiang Canada 17 321 1.0× 205 0.7× 524 1.9× 75 0.5× 73 0.6× 29 946
Ichiro Hamanaka Japan 18 577 1.9× 242 0.8× 496 1.8× 87 0.5× 47 0.4× 26 1.1k
Ebo DeMuinck United States 7 187 0.6× 158 0.6× 500 1.8× 173 1.1× 46 0.4× 8 843
Sava Kostin Germany 8 344 1.1× 184 0.6× 383 1.4× 155 1.0× 37 0.3× 9 851
Oriol Juan‐Babot Spain 20 296 1.0× 235 0.8× 391 1.4× 44 0.3× 74 0.7× 27 981
Yoshitane Seino Japan 13 393 1.3× 204 0.7× 200 0.7× 49 0.3× 90 0.8× 26 861
Eto Y Japan 14 176 0.6× 152 0.5× 436 1.6× 50 0.3× 73 0.6× 28 795
Bruce R. Ito United States 19 380 1.2× 169 0.6× 267 1.0× 129 0.8× 22 0.2× 28 1.1k

Countries citing papers authored by Masashi Namba

Since Specialization
Citations

This map shows the geographic impact of Masashi Namba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masashi Namba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masashi Namba more than expected).

Fields of papers citing papers by Masashi Namba

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masashi Namba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masashi Namba. The network helps show where Masashi Namba may publish in the future.

Co-authorship network of co-authors of Masashi Namba

This figure shows the co-authorship network connecting the top 25 collaborators of Masashi Namba. A scholar is included among the top collaborators of Masashi Namba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masashi Namba. Masashi Namba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miura, Shin‐ichiro, Hiroshi Iwamoto, Masashi Namba, et al.. (2024). High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosis. BMJ Open Respiratory Research. 11(1). e001803–e001803. 10 indexed citations
2.
Nakashima, Taku, Takeshi Masuda, Masashi Namba, et al.. (2023). Hypoxia-inducible factor 1α modulates interstitial pneumonia-mediated lung cancer progression. Journal of Translational Medicine. 21(1). 857–857. 2 indexed citations
3.
Nakashima, Taku, Keitaro Omori, Masashi Namba, et al.. (2023). Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases. Respiratory Medicine. 212. 107224–107224. 2 indexed citations
4.
Masuda, Takeshi, Taku Nakashima, Masashi Namba, et al.. (2023). Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial–Mesenchymal Transition. Cancers. 15(4). 1092–1092. 5 indexed citations
5.
Namba, Masashi, et al.. (2023). Concurrent Mutations in <i>STK11</i> and <i>KEAP1</i> Cause Treatment Resistance in <i>KRAS</i> Wild-type Non-small-cell Lung Cancer. Internal Medicine. 62(20). 3001–3004. 4 indexed citations
6.
Kawahara, Daisuke, Takeshi Masuda, Masashi Namba, et al.. (2022). Prediction model for patient prognosis in idiopathic pulmonary fibrosis using hybrid radiomics analysis. SHILAP Revista de lepidopterología. 4. 100017–100017. 1 indexed citations
7.
Takahashi, Hiroshi, Taku Nakashima, Takeshi Masuda, et al.. (2021). Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity. Stem Cell Research & Therapy. 12(1). 471–471. 6 indexed citations
8.
9.
10.
11.
Namba, Masashi, Takeshi Masuda, Hiroaki Terada, et al.. (2020). Extent of pulmonary fibrosis on high-resolution computed tomography is a prognostic factor in patients with pleuroparenchymal fibroelastosis. Respiratory Investigation. 58(6). 465–472. 13 indexed citations
12.
Abe, Manabu, Yukio Nishimura, Shoji Ishizaka, et al.. (2019). Photochemical generation of the 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) radical from caged nitroxides by near-infrared two-photon irradiation and its cytocidal effect on lung cancer cells. Beilstein Journal of Organic Chemistry. 15. 863–873. 12 indexed citations
13.
Namba, Masashi, Noboru Hattori, Hironobu Hamada, et al.. (2018). Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1. Cancer Letters. 442. 31–39. 15 indexed citations
14.
Tanaka, Atsushi, Kenei Shimada, Masashi Namba, et al.. (2009). Ruptured plaque is associated with larger infarct size following successful percutaneous coronary intervention in ST segment elevation acute myocardial infarction. Coronary Artery Disease. 20(4). 260–266. 13 indexed citations
15.
Tanaka, Atsushi, Kenei Shimada, Toshihiko Sano, et al.. (2005). Multiple Plaque Rupture and C-Reactive Protein in Acute Myocardial Infarction. Journal of the American College of Cardiology. 45(10). 1594–1599. 164 indexed citations
16.
Kim‐Mitsuyama, Shokei, Yoko Izumi, Yasuhiro Izumiya, et al.. (2005). Dominant-negative c-Jun inhibits rat cardiac hypertrophy induced by angiotensin II and hypertension. Gene Therapy. 13(4). 348–355. 17 indexed citations
17.
Oe, Hiroki, Masahiko Takagi, Atsushi Tanaka, et al.. (2005). Prevalence and Clinical Course of the Juveniles with Brugada‐Type ECG in Japanese Population. Pacing and Clinical Electrophysiology. 28(6). 549–554. 41 indexed citations
18.
Kotake, Kenjiro, Masashi Namba, Masakatsu Sunagawa, et al.. (1995). Neoadjuvant chemotherapy with tegafur suppository for rectal cancer - Effects of tegafur on nuclear DNA content of cancer cells. Gan to kagaku ryōhō. 22(6). 793–798. 1 indexed citations
19.
Kaiya, Hisanobu, et al.. (1977). Chlorpromazine induces population increase of synaptic vesicles in the rat hypothalamic ventromedial nucleus.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 12(3). 323–30. 2 indexed citations
20.
Tsuge, Kenya, et al.. (1958). Tendon transfers for claw hand. Okayama University Scientific Achievement Repository (Okayama University). 12(2). 157–173.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L Simonet Breakdown of academic impact, for papers by Toshiyuki Kozai Breakdown of academic impact, for papers by Fu-Li Xiang Breakdown of academic impact, for papers by Ichiro Hamanaka Breakdown of academic impact, for papers by Ebo DeMuinck Breakdown of academic impact, for papers by Sava Kostin Breakdown of academic impact, for papers by Oriol Juan‐Babot Breakdown of academic impact, for papers by Yoshitane Seino Breakdown of academic impact, for papers by Eto Y Breakdown of academic impact, for papers by Bruce R. Ito
Rankless by CCL
2026